by MM360 Staff | Sep 18, 2025 | Myeloma News
Source: Pharmacy Times articles An expert discusses CAR T therapy’s potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges. Read More
by MM360 Staff | Sep 17, 2025 | Myeloma News
Source: Pharmacy Times articles Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards. Read More
by MM360 Staff | Sep 15, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Sep 14, 2025 | Publications
Cancers (Basel). 2025 Aug 22;17(17):2727. doi: 10.3390/cancers17172727. ABSTRACT Background: Multiple myeloma (MM) is an incurable plasma cell dyscrasia with particularly adverse prognosis in relapsed, multi-drug refractory settings. The management of those patients...
by MM360 Staff | Sep 13, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More